Ascletis to Unveil New Obesity Treatments at ObesityWeek® 2025 Conference
Ascletis Pharma Inc., a leading biotechnology firm, is set to present its latest findings on a suite of promising obesity treatments at the upcoming ObesityWeek® 2025. The event, regarded as one of the foremost conferences for obesity-related research and clinical practices, will take place from November 4 to 7, 2025, in Atlanta, Georgia. Among the highlights of Ascletis' presentations are the results of studies on its investigational oral GLP-1 receptor (GLP-1R) small molecule agonist, ASC30, as well as promising data on the combined use of ASC31 and ASC47.
During the conference, Ascletis will feature three significant poster presentations. The first, titled "A Full Analysis of a 28-Day Multiple Ascending Dose Study of Oral GLP-1R Biased Small Molecule Agonist ASC30 for Obesity," will provide crucial insights into the safety and efficacy of this oral treatment option. The second presentation will focus on ASC30 as a once-monthly injected small molecule, showcasing its potential as a groundbreaking therapeutic option in weight management. Lastly, a comparative study will investigate the efficacy of the GLP-1R/GIPR peptide agonist combination, ASC31 and ASC47, demonstrating that this combination significantly surpasses the weight loss effects of the popular treatment Tirzepatide in diet-induced obese mice.
Dr. Jinzi Jason Wu, the Founder, Chairman, and CEO of Ascletis, remarked on the importance of these presentations, stating, "We are excited to present the ongoing advancements of our robust obesity portfolio. These developments reflect our unwavering commitment to providing highly differentiated therapeutic options for those suffering from obesity."
ASC30 is an oral GLP-1R biased small molecule that offers a unique dual administration route—available in both tablet and injection forms. The investigational drug is currently protected under compound patents in the U.S. and globally until 2044, ensuring its exclusive market position for a substantial period. On the other hand, ASC31 is a novel peptide agonist designed to target both GLP-1R and GIPR receptors, showing promising results in animal studies for weight loss efficacy. Furthermore, ASC47 is distinguished by its adipose-targeting properties, providing a focused approach that delivers concentrated drug doses to fat tissues.
ObesityWeek® stands at the forefront of obesity science, where researchers and healthcare professionals gather to exchange insights and breakthroughs in obesity treatment and prevention techniques. The conference serves as a crucial platform for discussing the latest clinical research, state-of-the-art therapies, and advocacy efforts related to metabolic health. This year's conference aims to broaden understanding and deployment of obesity treatments amid the global rise in obesity rates.
Ascletis Pharma Inc. is committed to the development and commercialization of innovative therapeutics that target metabolic diseases, utilizing cutting-edge technologies including Artificial Intelligence-Assisted Structure-Based Drug Discovery. The Hong Kong-listed company aims to revolutionize obesity treatments through its lead drug candidate, ASC30, which represents a significant advancement in the accessibility and effectiveness of obesity therapies. To learn more, visit Ascletis.
Presentation Highlights
During the conference, Ascletis will feature three significant poster presentations. The first, titled "A Full Analysis of a 28-Day Multiple Ascending Dose Study of Oral GLP-1R Biased Small Molecule Agonist ASC30 for Obesity," will provide crucial insights into the safety and efficacy of this oral treatment option. The second presentation will focus on ASC30 as a once-monthly injected small molecule, showcasing its potential as a groundbreaking therapeutic option in weight management. Lastly, a comparative study will investigate the efficacy of the GLP-1R/GIPR peptide agonist combination, ASC31 and ASC47, demonstrating that this combination significantly surpasses the weight loss effects of the popular treatment Tirzepatide in diet-induced obese mice.
Dr. Jinzi Jason Wu, the Founder, Chairman, and CEO of Ascletis, remarked on the importance of these presentations, stating, "We are excited to present the ongoing advancements of our robust obesity portfolio. These developments reflect our unwavering commitment to providing highly differentiated therapeutic options for those suffering from obesity."
Understanding the Pipeline
ASC30 is an oral GLP-1R biased small molecule that offers a unique dual administration route—available in both tablet and injection forms. The investigational drug is currently protected under compound patents in the U.S. and globally until 2044, ensuring its exclusive market position for a substantial period. On the other hand, ASC31 is a novel peptide agonist designed to target both GLP-1R and GIPR receptors, showing promising results in animal studies for weight loss efficacy. Furthermore, ASC47 is distinguished by its adipose-targeting properties, providing a focused approach that delivers concentrated drug doses to fat tissues.
About ObesityWeek®
ObesityWeek® stands at the forefront of obesity science, where researchers and healthcare professionals gather to exchange insights and breakthroughs in obesity treatment and prevention techniques. The conference serves as a crucial platform for discussing the latest clinical research, state-of-the-art therapies, and advocacy efforts related to metabolic health. This year's conference aims to broaden understanding and deployment of obesity treatments amid the global rise in obesity rates.
Ascletis Pharma Profile
Ascletis Pharma Inc. is committed to the development and commercialization of innovative therapeutics that target metabolic diseases, utilizing cutting-edge technologies including Artificial Intelligence-Assisted Structure-Based Drug Discovery. The Hong Kong-listed company aims to revolutionize obesity treatments through its lead drug candidate, ASC30, which represents a significant advancement in the accessibility and effectiveness of obesity therapies. To learn more, visit Ascletis.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.